Ok_老虎社区_美港股上老虎

aiyohyun
2021-10-14

Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>

New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.

Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":825234430,"tweetId":"825234430","gmtCreate":1634226446182,"gmtModify":1634226446334,"author":{"id":3582936698066263,"idStr":"3582936698066263","authorId":3582936698066263,"authorIdStr":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Ok</body></html>","htmlText":"<html><head></head><body>Ok</body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/825234430","repostId":1151136903,"repostType":4,"repost":{"id":"1151136903","kind":"news","pubTimestamp":1634225065,"share":"https://www.laohu8.com/m/news/1151136903?lang=zh_CN&edition=full","pubTime":"2021-10-14 23:24","market":"us","language":"en","title":"Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1151136903","media":"Motley Fool","summary":"New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.","content":"Key Points<blockquote>要点</blockquote> <ul> <li>An infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.</li> <li>Aviptadil is in development for the treatment of respiratory failure related to severe COVID infection.</li> <li>The peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.</li> </ul> What happened<blockquote><ul><li>一份传染病杂志发表了NRx Pharmaceuticals的主要候选药物aviptadil的临床试验结果。</li><li>阿维他地尔正在开发中，用于治疗与严重COVID感染相关的呼吸衰竭。</li><li>同行评审结果是积极的，但不足以支持FDA的紧急使用授权请求。</li></ul>发生了什么</blockquote> Shares of&nbsp;NRx Pharmaceuticals(NASDAQ:NRXP)&nbsp;are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some&nbsp;positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.<blockquote>本公司之股份NRx制药公司（纳斯达克：NRXP）本周第二次大幅上涨。周二，在该公司转述了一些积极的监管进展后，该股跳涨。如今，投资者对aviptadil的临床试验结果感到兴奋，aviptadil是一种治疗COVID-19引起的呼吸衰竭的潜在新疗法。截至美国东部时间周四上午10:54，该生物科技股上涨33.8%。</blockquote> So what<blockquote>那又怎样</blockquote> This morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.<blockquote>今天早上，一份传染病杂志发表了一项针对阿维他地尔和危重COVID患者的开放标签试验的同行评审结果。令人印象深刻的是，81%接受阿维他地尔治疗的患者存活了至少60天，而接受标准治疗的患者仅存活了21%。</blockquote> <img src=\"https://static.tigerbbs.com/e2822fcb875474824949ad943caf5b99\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> The number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to&nbsp;market-beating gains&nbsp;for NRx Pharmaceuticals investors.<blockquote>自该研究以来，严重COVID感染的数量已大幅下降，但仍足以推动大幅销售。作为一家没有任何获批药物产生收入的临床阶段公司，即使aviptadil的适度销售也可能为NRx Pharmaceuticals投资者带来跑赢市场的收益。</blockquote> Now what<blockquote>现在怎么办</blockquote> Unfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.<blockquote>不幸的是，我们仍然不知道NRx Pharmaceuticals何时有机会推出aviptadil。今天展示的结果很有趣，但还有更多工作要做。</blockquote> Today's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.<blockquote>今天的公告来自一项在单一医院系统中进行的开放标签试验，没有任何随机化。研究人员简单地治疗了2020年夏天休斯顿一家医院系统收治的21名连续合格患者。</blockquote> In place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.<blockquote>代替安慰剂，研究者使用了该组前后入院的具有类似合并症的患者，这些患者接受了阿维他地尔治疗。这些结果很有趣。然而，它们本身不足以支持紧急使用授权请求。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-10-14 23:24\n\n</h4>\n</header>\n<article>\nKey Points<blockquote>要点</blockquote> <ul> <li>An infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.</li> <li>Aviptadil is in development for the treatment of respiratory failure related to severe COVID infection.</li> <li>The peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.</li> </ul> What happened<blockquote><ul><li>一份传染病杂志发表了NRx Pharmaceuticals的主要候选药物aviptadil的临床试验结果。</li><li>阿维他地尔正在开发中，用于治疗与严重COVID感染相关的呼吸衰竭。</li><li>同行评审结果是积极的，但不足以支持FDA的紧急使用授权请求。</li></ul>发生了什么</blockquote> Shares of&nbsp;NRx Pharmaceuticals(NASDAQ:NRXP)&nbsp;are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some&nbsp;positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.<blockquote>本公司之股份NRx制药公司（纳斯达克：NRXP）本周第二次大幅上涨。周二，在该公司转述了一些积极的监管进展后，该股跳涨。如今，投资者对aviptadil的临床试验结果感到兴奋，aviptadil是一种治疗COVID-19引起的呼吸衰竭的潜在新疗法。截至美国东部时间周四上午10:54，该生物科技股上涨33.8%。</blockquote> So what<blockquote>那又怎样</blockquote> This morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.<blockquote>今天早上，一份传染病杂志发表了一项针对阿维他地尔和危重COVID患者的开放标签试验的同行评审结果。令人印象深刻的是，81%接受阿维他地尔治疗的患者存活了至少60天，而接受标准治疗的患者仅存活了21%。</blockquote> <img src=\"https://static.tigerbbs.com/e2822fcb875474824949ad943caf5b99\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> The number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to&nbsp;market-beating gains&nbsp;for NRx Pharmaceuticals investors.<blockquote>自该研究以来，严重COVID感染的数量已大幅下降，但仍足以推动大幅销售。作为一家没有任何获批药物产生收入的临床阶段公司，即使aviptadil的适度销售也可能为NRx Pharmaceuticals投资者带来跑赢市场的收益。</blockquote> Now what<blockquote>现在怎么办</blockquote> Unfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.<blockquote>不幸的是，我们仍然不知道NRx Pharmaceuticals何时有机会推出aviptadil。今天展示的结果很有趣，但还有更多工作要做。</blockquote> Today's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.<blockquote>今天的公告来自一项在单一医院系统中进行的开放标签试验，没有任何随机化。研究人员简单地治疗了2020年夏天休斯顿一家医院系统收治的21名连续合格患者。</blockquote> In place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.<blockquote>代替安慰剂，研究者使用了该组前后入院的具有类似合并症的患者，这些患者接受了阿维他地尔治疗。这些结果很有趣。然而，它们本身不足以支持紧急使用授权请求。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151136903","content_text":"Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory failure related to severe COVID infection.\nThe peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.\n\nWhat happened\nShares of NRx Pharmaceuticals(NASDAQ:NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.\nSo what\nThis morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.\nIMAGE SOURCE: GETTY IMAGES.\nThe number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.\nNow what\nUnfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.\nToday's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.\nIn place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.","news_type":1,"symbols_score_info":{"NRXP":0.9}},"isVote":1,"tweetType":1,"viewCount":3204,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>

评论（1）

热议股票